With one & a half decades experience in pharmaceutical sales and marketing, I am a confident, ambitious, and performance-driven professional who strives to excel in the creative and challenging field of healthcare. I have a strong core understanding of formulating and implementing strategies, a result-driven attitude, and a versatile experience in handling orals, injectables, and innovative products, including biologics, biosimilars, and new chemical entities (NCEs).As the General Manager at Zydus Group for BioNext division , I lead the sales and marketing team for the gastroenterology and hepatology portfolio, with a focus on non-alcoholic steatohepatitis (NASH), inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and Viral hepatitis. I have successfully launched and managed the flagship brands Exemptia, the first ever biosimilar of adalimumab, and Bilypsa (Saroglitazar), the first ever NCE by an Indian company and the first drug to be approved anywhere in the world for NAFLD & NASH. I have also conceptualized and led multiple novel initiatives focused on engaging key doctors, therapy awareness, market creation, and patient management at the national and global level. Additionally, I serve as the office bearer and lead of the Pharmaceutical Council, WICCI , where I collaborate with industry peers and stakeholders to advance the interests and goals of the sector. I enjoy working with individuals at all levels from diverse cultures and disciplines, and I have a positive and supportive attitude towards work and life. I am open to challenges and comfortable in leading and working in teams. I have considerable experience of working under pressure and always ready to go that extra mile. My areas of interest include strategic management, business development, training and people development. My mission is to leverage my expertise and passion to create and deliver value for patients, customers, and society.